Aprotinin in perspective

The Annals of Thoracic Surgery

Volumn 55, Issue 4, 1993, Pages 1033-1041

  Westaby, Stephen ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; PLASMIN;

BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CORONARY ARTERY SURGERY; PRIORITY JOURNAL; REVIEW;

APROTININ; CARDIOPULMONARY BYPASS; HEMOSTASIS; HUMAN; KIDNEY;

EID: 0027300477     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(93)90149-C     Document Type: Review

References (72)

1. Aprotinin therapy for reoperative myocardial revascularization: A placebocontrolled study
2. The disulphide linkages in kallekrein inactivator of bovine lung
3. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs
4. Distribution, half life time, and placental transfer of the protease inhibitor Trasylol
5. In vivo interaction of the Kunitz protease inhibitor and of insulin with subcellular structures from rat renal cortex
6. Recent experimental results regarding protease inhibitors
7. Das Verhalten des Trasylol im Organismus als Modell fur die Pharmakokinetik basischer Polypeptide
8. Effects of Trasylol on the kidneys—dependence on temperature and dose
9. Effect of aprotinin on renal function
10. High dose aprotinin (Trasylol) therapy—harmless to the kidney
11. Immunological behaviour of proteolytic enzyme inhibitors
12. On the treatment of pancreatitis
13. Protective action of a protease inhibitor in haemorrhagic shock
14. Prophylaxis of post traumatic pulmonary insufficiency by protease inhibitor therapy with aprotinin: a clinical study
15. Field study on the therapeutic value of Trasylol in traumatic shock
16. The inhibition by Trasylol of fibrinolytic activity associated with cardiovascular operations
17. Natural protease inhibitors in extracorporeal circulation
18. Aprotinin bei Operationen am offen Herzen
19. Einsatz von Proteinasen inhibitoren waehrend der extrakorporalen Zirkulation Wirkungs-verbesserung durch Optimierung der Dosis in einer klinischen Studie
20. Aprotinin-ACD-Blut I. Experimen-telle Untersuchungen uber den Einfluss von Aprotinin auf die plasmatische und thrombozytare Gerinnung
21. Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit
22. Complement and the damaging effects of cardiopulmonary bypass
23. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass
24. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin
25. High-dose aprotinin: hemostatic effects in open heart operations
26. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass
27. Aprotinin in aspirin-pretreated patients
28. Effect of aprotinin on need for blood transfusions after repeat open heart surgery
29. Bleeding after cardiopulmonary bypass
30. Mechanisms of abnormal bleeding in patients undergoing cardiopulmonary bypass. Acquired transient platelet dysfunction associated with selected alpha-granule release
31. Platelet aggregate emboli produced in patients during cardiopulmonary bypass with membrane and bubble oxygenators and blood filters
32. Platelet function during cardiac operation
33. Significant reduction in the binding of a monoclonal antibody (LYP 18) directed against the IIb/IIa glycoprotein complex to platelets of patients have undergone extracorporeal circulation
34. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass
35. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass
36. Platelet preservation during cardiopulmonary bypass with aprotinin
37. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions
38. Fibrinogen receptors in platelet adhesion to the subendothelium
39. The serine antiprotease aprotinin (Trasylol): a novel approach to reducing post operative bleeding
40. Pharmacology of aprotinin and efficacy during cardiopulmonary bypass
41. Initiation of blood coagulation at artificial surfaces
42. Plasminogen interacts with human platelets through two distinct mechanisms
43. Role of the contact system in fibrinolysis
44. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator
45. Surface activation of blood coagulation, fibrinolysis and kinin formation
46. Increased anticoagulation during cardiopulmonary bypass by aprotinin
47. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass
48. Cardiopulmonary bypass and haemostasis
49. Heparin binding to resting and activated platelets
50. Fluorescent labelled aprotinin a new reagent for the histochemical detection of acid muco-substances
51. Preoperative assessment of hemostatic activity to predict excessive blood loss after cardiopulmonary bypass
52. Normal haemostasis and its regulation
53. Regulation of the coagulation system by vascular endothelial cells
54. The role of protein C in congenital and acquired thrombotic disorders
55. Cytokine responses to cardiopulmonary bypass with membrane and bubble oxygenation
56. Tumour necrosis factor leads to the internalisation and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture
57. Aprotinin (Trasylol) is a competetive inhibitor of activated protein C
58. Hypothermia and blood coagulation. Dissociation between enzyme activity and clotting factor levels
59. Changes in coagulation and fibrinolysis occurring in dogs during hypothermia
60. Effect of hypothermia on enzymatic activity of thrombin and plasmin
61. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations
62. Dipyridamole preserved platelets and reduced blood loss after cardiopulmonary bypass
63. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery
64. The role of epsilon amino-caproic acid in reducing bleeding after cardiac operations: a double blind study
65. Aprotinin therapy in cardiac surgery
66. Determinants of blood utilization during myocardial revascularization
67. Transfusion of predonated autologous blood in elective cardiac-surgery
68. Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application—clinical experience in 152 cardiac surgical patients
69. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin—preliminary results
70. Aprotinin in paediatric cardiac surgery
71. Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open heart surgery